Skip to main content

Table 1 Characteristics of the included datasets for Group A in the present study

From: An integrative transcriptome analysis reveals potential predictive, prognostic biomarkers and therapeutic targets in colorectal cancer

TNM Staging

Groups

# Samples

(Cases/Control)

Platform

Genes

DEGs (UR/DR)

Stage I

GSE35602

13 (5/8)

GPL6480

41,108

3635 (2629/1006)

GSE41258

81 (27/54)

GPL96

22,283

924 (366/558)

GSE89076

42 (8/34)

GPL16699

62,976

4953 (2649/2304)

GSE117606

74 (15/59)

GPL25373

19,276

424 (156/268)

GSE71187

25 (13/12)

GPL6480

41,108

3784 (1535/2249)

TCGA-COAD

125 (84/41)

Illumina

56,499

4520 (1631/2889)

TCGA-READ

41 (31/10)

Illumina

56,493

4918 (1640/3278)

Stage II

GSE35602

16 (8/8)

GPL6480

41,108

4427 (2542/1885)

GSE41258

103 (49/54)

GPL96

22,283

808 (281/527)

GSE89076

42 (8/34)

GPL16699

62,976

4606 (2596/2010)

GSE117606

72 (23/59)

GPL25373

19,276

562 (232/329)

GSE71187

29 (17/12)

GPL6480

41,108

3656 (1384/2272)

TCGA-COAD

132 (191/41)

Illumina

56,499

4660 (1684/2976)

TCGA-READ

64 (54/10)

Illumina

56,493

4694 (1580/3114)

Stage III

GSE35602

18 (10/8)

GPL6480

54,675

2918 (2047/871)

GSE41258

102 (48/54)

GPL96

22,283

800 (330/470)

GSE83889

128 (93/35)

GPL10558

48,107

1501 (922/579)

GSE89076

42 (11/34)

GPL16699

62,976

4955 (2787/2168)

GSE117606

73 (24/59)

GPL25373

19,276

477 (184/293)

GSE71187

63 (51/12)

GPL6480

41,108

3363 (1268/2095)

TCGA-COAD

176 (135/41)

Illumina

56,499

4562 (1614/2948)

TCGA-READ

64 (54/10)

Illumina

56,493

4863 (1763/3100)

Stage IV

GSE41258

109 (55/54)

GPL96

22,283

796 (297/499)

GSE89076

38 (6/34)

GPL16699

62,976

4798 (2460/2338)

GSE71187

18 (6/12)

GPL6480

41,108

4584 (1803/2781)

GSE49355

36 (20/16)

GPL96

22,283

814 (357/457)

TCGA-COAD

109 (68/41)

Illumina

56,499

4619 (1657/2962)

TCGA-READ

35 (25/10)

Illumina

56,493

4568 (1844/2724)